Back

Praxis Precision Medicines stock surges over 1,000% since April 2025

Verifying
  • Praxis Precision Medicines' stock surged following positive clinical results for two drug candidates.
  • Over 1,000% was the stock's gain since April 2025.
  • Ulixacaltamide and relutrigine are expected to reach FDA review in 2026–2027.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.